Immunogenicity and safety of BNT162b2 mRNA vaccine in Chinese adults: A phase 2 randomised clinical trial

BACKGROUND: BNT162b2, an mRNA vaccine against COVID-19, is being utilised worldwide, but immunogenicity and safety data in Chinese individuals are limited. METHODS: This phase 2, randomised, double-blind, placebo-controlled trial included healthy or medically stable individuals aged 18–85 years enro...

Descripción completa

Detalles Bibliográficos
Autores principales: Hui, Ai-Min, Li, Jingxin, Zhu, Li, Tang, Rong, Ye, Huayue, Lin, Mei, Ge, Lei, Wang, Xiyuan, Peng, Fuzhong, Wu, Zhenggang, Guo, Xiling, Shi, Yunfeng, Pan, Hongxing, Zhu, Jiahong, Song, Zhizhou, Qiu, Jingjun, Wang, Wei, Zheng, Jianfei, Ozhelvaci, Orkun, Shpyro, Svetlana, Bushway, Meghan, Derhovanessian, Evelyna, Kühnle, Marie-Cristine, Luxemburger, Ulrich, Muik, Alexander, Shishkova, Yoana, Khondker, Zakaria, Hu, Simin, Lagkadinou, Eleni, Şahin, Uğur, Türeci, Özlem, Zhu, Fengcai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472569/
https://www.ncbi.nlm.nih.gov/pubmed/36120090
http://dx.doi.org/10.1016/j.lanwpc.2022.100586

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472569/
https://www.ncbi.nlm.nih.gov/pubmed/36120090
http://dx.doi.org/10.1016/j.lanwpc.2022.100586

Ejemplares similares